1
|
Fakih M, Ouyang C, Wang C, Tu T, Cho M, Sy M, Longmate J, Lee P. High PD-L1 expression and high CD8+ T-cell infiltration identifies a new subpopulation of colorectal cancer with high risk of relapse and poor outcome. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Rosa CL, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA. La Rosa C et al (J Infect Dis 2012; 205:1294-304). J Infect Dis 2013. [DOI: 10.1093/infdis/jit282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Shibata S, Longmate J, Chung VM, Lenz H, Kummar S, Sarantopoulos J, Harrison ML, Synold TW, Ivy SP, Newman EM. A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2571] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Lara P, Longmate J, Argiris A, Gitlitz BJ, Mack PC, Lau DH, Koczywas M, Leighl NB, Gandara DR. Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Shek DW, Longmate J, Quinn D, Margolin K, Twardowski P, Gandara D, Pan C, Lara P. A phase II trial of gefitinib and pegylated interferon alfa 2b (PEG-IFN) in previously-treated renal cell carcinoma (RCC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16115 Background: Modulation of the epidermal growth factor receptor (EGFR) pathway is relevant to IFN activity in RCC. Cell lines sensitive to IFN's antiproliferative effects downregulate EGFR, while IFN treatment of resistant cells precludes such an effect. (Eisenkraft et al, Cancer Res. 1991) Lack of EGFR down-regulation may thus be responsible in part for IFN resistance. To explore this hypothesis, we conducted a trial of the EGFR tyrosine kinase inhibitor gefitinib plus PEG-IFN in RCC patients (pts). Methods: Unresectable or metastatic RCC pts (no limit on prior therapies; performance status 0–2, and adequate end-organ function) were eligible. Prior IFN was allowed. Dose schedule: PEG-IFN SQ weekly (6μg/kg/week or 4 μg/kg/week) × 12 weeks and gefitinib 250 mg po daily until progression. A 6-month progression free survival (PFS) rate of 50% was considered promising (vs. 30%) in a two-stage design incorporating the Green-Dahlberg rule. We accrued 21 patients in the first-stage of accrual. Results: Pt characteristics: Males -16; median age - 56 years; Prior nephrectomy - 12. All had > 1 prior systemic therapy . Accrual slowed with increased use of small molecule kinase inhibitors, bevacizumab, and temsirolimus for RCC. At 6 months, PFS was 26% (95% CI: 9%, 49%); 20% (4 pts) had died. Best responses by RECIST: complete (1), partial (4), stable (8); progression (4). Response duration: CR (35+ months) and PR (3, 5, 5, 38+ months). Median time to treatment failure was 18.4 weeks (95%CI: 7.4, 24.9). Median PFS and overall survival were 23 and 53 weeks, respectively. Most common treatment-related toxicities were leucopenia, thrombocytopenia, rash, nausea, diarrhea, and hyperglycemia. Conclusions: Although gefitinib plus PEG-IFN did not meet the pre-specified 6-month PFS of 50%, it appears to have activity similar to other first-line therapies even in this previously-treated setting. (Supported by Astra Zeneca) [Table: see text]
Collapse
Affiliation(s)
- D. W. Shek
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| | - J. Longmate
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| | - D. Quinn
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| | - K. Margolin
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| | - P. Twardowski
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| | - D. Gandara
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| | - C. Pan
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| | - P. Lara
- University of California Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; University of Southern California, Los Angeles, CA; University of Washington, Seattle, CA
| |
Collapse
|
6
|
Ramalingam SS, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Belani CP, Gandara DR. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8078] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Ngyuen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN. Beyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer 2007; 17:373-8. [PMID: 17362315 DOI: 10.1111/j.1525-1438.2007.00787.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics. OC patients relapsing following platinum-based chemotherapy received CBDCA area under the curve (AUC 3) with CSA and IFN, every 3 weeks. The pharmacokinetics of CSA and CBDCA were determined in a subset of patients. Thirty patients received 84 courses of therapy. Three partial responses were observed. Nine patients were stable for >4 months. Toxicity was similar to that observed in our previously reported phase I study and consisted of myelosuppression, nausea, vomiting, and headache. The mean end of infusion CSA level (high-performance liquid chromatographic assay [HPLC]) was 1109 +/- 291 microg/mL (mean +/- SD). CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance. Steady-state levels of >1 microg/mL CSA (HPLC assay) are achievable in vivo. Insufficient clinical resistance reversal was observed in this study to warrant further investigation of this combination.
Collapse
Affiliation(s)
- R J Morgan
- Division of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Gandara DR. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4010] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4010 Background: Advanced BTC (gallbladder, bile duct) and HCC respond poorly to systemic chemotherapy. Lapatinib is an oral inhibitor of EGFR and Her/2-neu with evidence of activity in a number of tumor types. Both BTC and HCC overexpress EGFR 1 and 2. In addition, Her2/neu somatic mutations have been reported in HCC, and may predict response to EGFR targeted agents (Bekaii-Saab et al, A 4037, ASCO 2005). This trial conducted by the CCC-P and Univ. Chicago, is designed to determine the efficacy of lapatinib in BTC and HCC pts. Methods: A two-stage design is utilized and pts are stratified by tumor type (BTC or HCC); the study has a 90% power to detect a true response rate ≥20%. Two initial groups of 17 patients for BTC and HCC were accrued; one response from each was required to proceed with accrual to a total of 37 patients in each group. Adequate hematologic, renal, and hepatic function is required. Eligible pts are in Child A group and have ECOG PS of 0–2. One prior treatment regimen is allowed. Lapatinib dose is 1,500 mg/d orally without interruption. One cycle is 28 days and radiological assessment is done every 8 weeks. Results: 49 pts have been accrued (BTC 19 and HCC 30). Pt Characteristics: Male 59%, ECOG PS 0 (18 pts), ECOG PS 1 (22 pts). Median age 66 yrs (range19–82). Median cycles 2 (range 1–12). Grade 3/4 toxicity was noted in 19 pts and included fatigue in 4 pts, elevation of liver enzymes in 4 pts and diarrhea in 2 pts. Nausea, vomiting, rash, anemia and thrombocytopenia were noted in 1 pt each. There was no evidence of cardiac dysfunction. In 17 evaulable pts with BTC, no responses were observed, 5 had stable disease (SD). Among the first 17 pts with HCC, 2 confirmed partial responses have been recorded. In addition 8 pts have SD. The progression free survival is 1.8 mo for both BTC and HCC. Tumor and blood specimens are being analyzed for expression of EGFR, HER-2/neu, status of downstream signal pathway molecules, and correlation to response. Conclusions: Lapatinib is well-tolerated. No activity in BTC was noted and that cohort is closed. Lapatinib activity in HCC is encouraging, and study is close to completion. Source of support: NCI-NO1-CM-57018–16. [Table: see text]
Collapse
Affiliation(s)
- R. K. Ramanathan
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - C. P. Belani
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - D. A. Singh
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - M. Tanaka
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - H. J. Lenz
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - Y. Yen
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - H. L. Kindler
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - S. Iqbal
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - J. Longmate
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| | - D. R. Gandara
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Chicago, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; USC Norris Cancer Center, Los Angeles, CA; City of Hope, Duarte, CA
| |
Collapse
|
10
|
Lara PN, Longmate J, Stadler W, van Loan M, Wexler J, Quinn DI, Twardowski P, Vokes EE, Gandara DR. Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4569] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. N. Lara
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - J. Longmate
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - W. Stadler
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - M. van Loan
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - J. Wexler
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - D. I. Quinn
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - P. Twardowski
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - E. E. Vokes
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| | - D. R. Gandara
- UC Davis Cancer Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Chicago, Chicago, IL; US Dept of Agricul, Davis, CA; UC Davis Sch of Medicine, Sacramento, CA; Univ of Southern CA, Los Angeles, CA
| |
Collapse
|
11
|
Chee KG, Lara PN, Longmate J, Twardowski P, Quinn DI, Chatta G, Gandara DR. The AKT inhibitor perifosine in biochemically recurrent, hormone-sensitive prostate cancer (HSPC): A phase II California Cancer Consortium trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4642] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. G. Chee
- UC Davis Medcl Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Southern CA Norris Cancer Ctr, Los Angeles, CA; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA
| | - P. N. Lara
- UC Davis Medcl Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Southern CA Norris Cancer Ctr, Los Angeles, CA; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA
| | - J. Longmate
- UC Davis Medcl Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Southern CA Norris Cancer Ctr, Los Angeles, CA; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA
| | - P. Twardowski
- UC Davis Medcl Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Southern CA Norris Cancer Ctr, Los Angeles, CA; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA
| | - D. I. Quinn
- UC Davis Medcl Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Southern CA Norris Cancer Ctr, Los Angeles, CA; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA
| | - G. Chatta
- UC Davis Medcl Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Southern CA Norris Cancer Ctr, Los Angeles, CA; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA
| | - D. R. Gandara
- UC Davis Medcl Ctr, Sacramento, CA; City of Hope Comprehensive Cancer Ctr, Duarte, CA; Univ of Southern CA Norris Cancer Ctr, Los Angeles, CA; Univ of Pittsburgh Cancer Ctr, Pittsburgh, PA
| |
Collapse
|
12
|
Shibata SI, Pezner R, Chu D, Doroshow JH, Chow WA, Leong LA, Margolin KA, McNamara MV, Morgan RJ, Raschko JW, Somlo G, Tetef ML, Yen Y, Synold TW, Wagman L, Vora N, Carroll M, Lin S, Longmate J. A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies. Eur J Surg Oncol 2004; 30:650-7. [PMID: 15256240 DOI: 10.1016/j.ejso.2003.11.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/12/2003] [Indexed: 11/26/2022] Open
Abstract
AIM We describe the feasibility of combining infusional 5-fluorouracil (5-FU) with intraoperative radiation therapy (IORT). METHODS Patients with surgically resectable locally advanced gastrointestinal cancers were treated concurrently during surgery with IORT and a 72 h infusion of 5-FU. Patients without previous external beam radiation therapy (EBRT) were subsequently treated with EBRT (40-50Gy) concurrent with a 21-day continuous infusion of 5-FU. Pancreatic, gastric, duodenal, ampullary, recurrent colorectal, and recurrent anal cancer were included. RESULTS During IORT/5-FU, no chemotherapy-related grade III or IV hematologic or gastrointestinal toxicity was noted. Post-surgical recovery or wound healing was not affected. One of nine patients who received post-operative radiation required a treatment break. During follow-up, there were more complications in patients with pelvic tumours, especially those with previous radiation. Nine patients have had local and/or local regional recurrences, two of these in the IORT field. CONCLUSIONS Treatment with a combination of IORT and 5-FU followed by EBRT and 5-FU is feasible. However, long-term complications may be increased in previously irradiated recurrent pelvic tumours.
Collapse
Affiliation(s)
- S I Shibata
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Lara PN, Longmate J, Stadler W, Quinn DI, Twardowski P, Martel CI, Vogelzang NJ, Vokes EE, Doroshow JH, Gandara DR. Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4647] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. N. Lara
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - J. Longmate
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - W. Stadler
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - D. I. Quinn
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - P. Twardowski
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - C. I. Martel
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - N. J. Vogelzang
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - E. E. Vokes
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - J. H. Doroshow
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| | - D. R. Gandara
- UC Davis Cancer Center, Sacramento, CA; City of Hope, Duarte, CA; U of Chicago, Chicago, IL; Univ of Southern California, Los Angeles, CA
| |
Collapse
|
14
|
Mack PC, Lara PN, Longmate J, Gumerlock PH, Synold TW, Doroshow JH, Gandara DR. Phase I and correlative science trial of UCN-01 plus cisplatin (CDDP) in advanced solid tumors: A California Cancer Consortium study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9591] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. C. Mack
- UC Davis Cancer Center, Sacramento, CA; City of Hope Cancer Center, Duarte, CA
| | - P. N. Lara
- UC Davis Cancer Center, Sacramento, CA; City of Hope Cancer Center, Duarte, CA
| | - J. Longmate
- UC Davis Cancer Center, Sacramento, CA; City of Hope Cancer Center, Duarte, CA
| | - P. H. Gumerlock
- UC Davis Cancer Center, Sacramento, CA; City of Hope Cancer Center, Duarte, CA
| | - T. W. Synold
- UC Davis Cancer Center, Sacramento, CA; City of Hope Cancer Center, Duarte, CA
| | - J. H. Doroshow
- UC Davis Cancer Center, Sacramento, CA; City of Hope Cancer Center, Duarte, CA
| | - D. R. Gandara
- UC Davis Cancer Center, Sacramento, CA; City of Hope Cancer Center, Duarte, CA
| |
Collapse
|
15
|
Margolin KA, Longmate J, Baratta T, Synold T, Weber J, Gajewski T, Quirt I, Christensen S, Doroshow JH. CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7523] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. A. Margolin
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - J. Longmate
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - T. Baratta
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - T. Synold
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - J. Weber
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - T. Gajewski
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - I. Quirt
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - S. Christensen
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| | - J. H. Doroshow
- City of Hope, Duarte, CA; USC-Norris Cancer Center, Los Angeles, CA; University of Chicago Medical School, Chicago, IL; Princess Margaret Hospital, Toronto, ON, Canada; University of California, Davis, Sacramento, CA
| |
Collapse
|
16
|
Abstract
PURPOSE The objective of this report is to review the research methods that have been used in the design, analysis, and reporting of Phase I dose-escalation studies of high-dose chemotherapy (HDCT) with bone marrow or stem cell support and to propose new guidelines for such studies that incorporate emerging principles of pharmacology, toxicity assessment, statistical design, and long-term follow-up. METHODS We performed a search of original, English-language, peer-reviewed full-length reports of HDCT (with or without radiotherapy) and unmanipulated hematopoietic precursor support (autologous bone marrow or stem cells or allogeneic bone marrow) in which one or more drug doses were escalated to identify dose-limiting toxicities needed for the design of subsequent Phase II trials. We reviewed the design, execution, analysis, and reporting of these trials to develop a coherent set of guidelines for the initiation of new HDCT regimens. The primary elements included in our analysis were the technique of dose escalation, the choice and application of toxicity grading scale, and the pharmacologic correlates of dose escalation. We also evaluated the methods employed to define dose-limiting toxicities and to select the maximum tolerated dose and the dose recommended for further study. We then examined whether subsequent Phase II trials based on these definitions corroborated the findings from the prior Phase I studies and summarized the findings from pharmacologic analyses that were reported from a subset of these investigations. RESULTS Thirty-five reports met the criteria for our literature review. Two standard methods of dose escalation (fixed increments or modified Fibonacci increments) were described in detail and were employed in the majority (30/35) of the studies. In 5 studies, the details of dose escalation were either not provided or not adequately referenced. There was marked heterogeneity among toxicity grading methods; scales used included the National Cancer Institute Common Toxicity Criteria (or similar scales such as the United States cooperative group or World Health Organization scales) as well as substantially modified versions of those instruments. Wide variations in the methods used to identify dose-limiting toxicities were observed. Statistical considerations, applied to the identification of the maximum tolerated or Phase II recommended dose, were similarly heterogeneous. Phase II trial designs varied from a simple expansion of the Phase I trial to separate, formally conducted studies. Nine Phase I trials featured pharmacologic analyses, and these ranged from simple pharmacokinetic evaluations to more complex analyses of the relationship between drug dose and the molecular targets of drug action. CONCLUSIONS Phase I clinical trials in the HDCT setting have been designed, analyzed, and reported using heterogeneous methods that limited their application to Phase II and II investigations. Moreover, correlative pharmacologic analyses have not been routinely undertaken during this critical Phase I stage. We propose guidelines for the design of new Phase I studies of HDCT based on 4 essential elements: (1) rational preclinical and clinical pharmacologic foundation for the regimen and for the agent selected for dose escalation; (2) incorporation of analytical pharmacology in the design and analysis of the regimen under investigation; (3) clear, prospective definitions of the dose- or exposure-limiting toxicities that can be distinguished from modality-dependent toxicities; selection of an appropriate toxicity grading scale, including an assessment of cumulative, delayed, and long-term effects of HDCT, particularly when designing tandem or repetitive cycle regimens; and (4) statistical input into the design, execution, analysis, interpretation, and reporting of these studies.
Collapse
Affiliation(s)
- K Margolin
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California USA.
| | | | | | | |
Collapse
|
17
|
Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, II Smith W, Dutcher P, Gollob J, Longmate J, Johnson D. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002; 128:214-8. [PMID: 11935312 DOI: 10.1007/s00432-002-0323-8] [Citation(s) in RCA: 107] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2001] [Accepted: 11/29/2001] [Indexed: 11/25/2022]
Abstract
PURPOSE To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain. BACKGROUND Patients with melanoma metastatic to the central nervous system (CNS) have an extremely poor prognosis and appear to benefit little from WBI. TMZ is an alkylating agent chemically similar to dacarbazine (DTIC) with good oral bioavailability and CNS penetration. TMZ has broad preclinical antitumor activity which in melanoma is comparable to that of DTIC. The combination of TMZ and WBI may provide enhanced antitumor activity against CNS metastasis from melanoma. PATIENTS AND METHODS Patients with measurable CNS metastases with or without systemic disease were treated with WBI, 30 Gray over ten fractions (days 1-5 and 8-12). TMZ, 75 mg small middle dotm(2 small middle dot)day, was started on day 1, continued daily for 6 weeks and repeated every 10 weeks. RESULTS Thirty-one patients were treated. There was one CNS complete response of 4.5 months and two CNS partial responses of 2 months and 7 months duration; the latter patient also had a 4-month complete remission of systemic metastases. Toxicities were limited to a single episode of grade 3 transaminase elevation and two episodes of grade 3 neutropenia, one complicated by fatal sepsis. The median progression-free interval for both CNS and extracranial sites was 2 months (range 1 week-11 months), and median survival 6 months (range 2-12 months). CONCLUSIONS WBI has lower than expected activity in CNS metastasis of malignant melanoma. Although TMZ can be safely administered with WBI, the combination has limited anti-tumor activity.
Collapse
Affiliation(s)
- K Margolin
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 2002; 19:335-40. [PMID: 11561695 DOI: 10.1023/a:1010626230081] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a Phase II trial of Dolastatin-10, 400 microg/m2 in patients with advanced melanoma who had received no prior chemotherapy. Dolastatin-10 pharmokinetics were evaluated in a subset of patients following courses 1 and 2. Twelve patients were treated with a median of 2 cycles of Dolastatin-10, and no patient experienced an objective response. The only grade >2 toxicities were grade 3 neutropenia uncomplicated by infection, occurring in 4 patients following the first treatment cycle. The total systemic clearance and volume of distribution at steady-state were 2.61 +/- 1.9 L/h/m2 and 28.4 +/- 13 L/m2, respectively. Due to prolonged terminal elimination. Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma.
Collapse
Affiliation(s)
- K Margolin
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, McGonigle K, Yen Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant 2001; 28:859-63. [PMID: 11781646 DOI: 10.1038/sj.bmt.1703243] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2001] [Accepted: 08/09/2001] [Indexed: 11/09/2022]
Abstract
This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m(2) over 96 h (days -12 to -8), etoposide 700 mg/m(2) every day x3 (days -6 to -4), and cyclophosphamide 4.2 g/m(2) on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/microl was 14 (range 10-42) and platelets <20,000/microl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.
Collapse
Affiliation(s)
- R J Morgan
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Villacres MC, Lacey SF, La Rosa C, Krishnan R, Auge C, Longmate J, Zaia JA, Leedom JM, Diamond DJ. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus. J Infect Dis 2001; 184:256-67. [PMID: 11443550 DOI: 10.1086/322028] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2000] [Revised: 03/28/2001] [Indexed: 11/03/2022] Open
Abstract
CD8(+) T lymphocyte function specific for human cytomegalovirus (CMV) was evaluated in 14 patients infected with human immunodeficiency virus (HIV) receiving highly active antiretroviral therapy (HAART) and 26 CMV-seropositive donors without HIV infection. Fifty-seven percent of the HIV-infected group had CMV-specific cytolytic activity in freshly isolated peripheral blood mononuclear cells (PBMC) against targets expressing CMV pp65. Both interferon (IFN)-gamma secretion by CD8(+) T cells and the frequency of human leukocyte antigen (HLA)-tetramer-positive T cells in HLA-A*0201-positive HIV-infected subjects correlated with CMV-specific cytolysis. In contrast, PBMC from healthy CMV-seropositive donors did not have either measurable CMV-specific cytolysis or secretion of IFN-gamma without in vitro stimulation. The T helper response to CMV antigens was vigorous in healthy CMV-seropositive donors but low in the cohort of HIV-infected patients. Potent CD8(+) cytotoxic T lymphocyte responses to CMV in HIV-infected patients receiving HAART is the converse of what is found in healthy CMV-seropositive subjects and may be the predominant adaptive immune response against CMV in HIV-infected patients.
Collapse
Affiliation(s)
- M C Villacres
- Laboratory of Vaccine Research, Department of Virology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol 2001; 48:22-8. [PMID: 11488520 DOI: 10.1007/s002800100293] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Although cisplatin is an important agent in non-small-cell lung cancer (NSCLC), de novo resistance is common and acquired resistance emerges rapidly during therapy. Proposed mediators of platinum resistance include the protein kinase C (PKC) signal transduction pathway and associated c-FOS overexpression. While estrogen administration has been reported to upregulate PKC and c-FOS expression, the triphenylethylenes tamoxifen and toremifene potentiate platinum cytotoxicity by inhibition of PKC. Downregulation of c-FOS expression has been reported to result from PKC inhibition. In view of these findings, we hypothesized that toremifene would reverse platinum resistance and that this interaction would be influenced by tumor estrogen receptor (ER) status. MATERIALS AND METHODS A phase II trial of high-dose toremifene (600 mg orally daily on days 1-7) plus cisplatin (50 mg/m2 intravenously on days 4 and 11) every 28 days in NSCLC patients was conducted. A group of 30 patients with metastatic NSCLC who had been previously treated with platinum-based therapy were enrolled. RESULTS All of the 30 patients were assessable for toxicity and 28 for tumor response. Therapy was well tolerated with minimal hematologic and non-hematologic toxicity. Common toxicity criteria grade 3 hematologic toxicity was seen in only three patients. Five patients achieved a partial response for an overall response rate of 18% (95% CI 6-37). Median overall survival was 8.1 months (95% CI 5.4-17). To assess PKC, ER, and c-Fos expression by immunohistochemistry, 12 informative pretreatment patient tumor specimens were obtained. Four patient tumor specimens were positive for one or both PKC isoforms (alpha and epsilon) while c-Fos was overexpressed in three. None of the responding patient tumors exhibited c-FOS or PKC-epsilon overexpression. ER expression was found to be infrequent (8%), contrasting with previous reports in this tumor type. CONCLUSION While this phase II study indicates that high-dose toremifene plus cisplatin is feasible, active, and well tolerated in NSCLC patients previously treated with platinum compounds, the mechanism of action remains unclear. Further study of this regimen is warranted.
Collapse
Affiliation(s)
- P N Lara
- Division of Hematology-Oncology, University of California Davis Cancer Center, Sacramento 95817, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer 2001; 84:1591-8. [PMID: 11401310 PMCID: PMC2363687 DOI: 10.1054/bjoc.2001.1835] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We assessed the feasibility and pharmacokinetics of high-dose infusional paclitaxel in combination with doxorubicin, cyclophosphamide, and peripheral blood progenitor cell rescue. Between October 1995 and June 1998, 63 patients with high-risk primary [stage II with >or= 10 axillary nodes involved, stage IIIA or stage IIIB inflammatory carcinoma (n = 53)] or with stage IV responsive breast cancer (n = 10) received paclitaxel 150-775 mg/m(2)infused over 24 hours, doxorubicin 165 mg/m(2)as a continuous infusion over 96 hours, and cyclophosphamide 100 mg kg(-1). There were no treatment-related deaths. Dose-limiting toxicity was reversible, predominantly sensory neuropathy following administration of paclitaxel at the 775 mg/m(2) dose level. Paclitaxel pharmacokinetics were non-linear at higher dose levels; higher paclitaxel dose level, AUC, and peak concentrations were associated with increased incidence of paraesthesias. No correlation between stomatitis, haematopoietic toxicities, and paclitaxel dose or pharmacokinetics was found. Kaplan-Meier estimates of 30-month event-free and overall survival for patients with primary breast carcinoma are 65% (95% CI; 51-83%) and 77% (95% CI; 64-93%). Paclitaxel up to 725 mg/m(2) infused over 24 hours in combination with with doxorubicin 165 mg/m(2) and cyclophosphamide 100 mg kg(-1) is tolerable. A randomized study testing this regimen against high-dose carboplatin, thiotepa and cyclophosphamide (STAMP V) is currently ongoing.
Collapse
Affiliation(s)
- G Somlo
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Morgan RJ, Synold T, Carr BI, Doroshow JH, Womack EP, Shibata S, Somlo G, Raschko J, Leong L, McNamara M, Chow W, Tetef M, Margolin K, Akman S, Longmate J. Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. Cancer Chemother Pharmacol 2001; 47:327-32. [PMID: 11345649 DOI: 10.1007/s002800000232] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE The purpose of these sequential phase I studies was to evaluate the antiemetic efficacy and pharmacokinetics of high-dose continuous infusion prochlorperazine. METHODS A total of 52 patients with advanced cancer were treated in two sequential phase I studies utilizing high-dose prochlorperazine. In study 1, designed to investigate the antiemetic effects of dose-intensive prochlorperazine, various cisplatin-based multiagent chemotherapeutic regimens were administered in combination with escalating doses of prochlorperazine. In study 2, a fixed dose of cisplatin (60 mg/m2) was administered over 24 h as a continuous intravenous infusion in combination with infusional high-dose prochlorperazine. Antiemetic efficacy in the first trial was assessed in terms of the number of episodes of nausea, retching, and/or emesis during the 24 h following cisplatin administration. The pharmacokinetics of high-dose prochlorperazine were evaluated in eight patients treated in study 2 at the two dose levels below those at which dose-limiting toxicity was noted. RESULTS The maximally tolerated dose of prochlorperazine in combination with cisplatin (60 mg/m2 administered as a continuous infusion over 24 h) was 24 mg/h. The dose-limiting toxicity was grade 4 agitation and confusion noted in one patient treated at 26 mg/h. This patient died 3 days following cessation of chemotherapy due to the toxicity of the regimen in combination with the debilitating pulmonary effects of the disease. The mean end of infusion prochlorperazine level at the 24 mg/h dose level was 1.1 microM, a concentration previously reported to be consistent with the reversal of the multidrug resistance phenotype. Two partial responses were observed in study 2. CONCLUSIONS We conclude that the antiemetic efficacy of high-dose infusional prochlorperazine does not appear to be improved over more convenient bolus administration. However, prochlorperazine levels consistent with those required in vitro for drug resistance reversal are attainable within the dose range having a tolerable toxicity profile.
Collapse
Affiliation(s)
- R J Morgan
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ren RL, Vora N, Yang F, Longmate J, Wang W, Sun H, Li JR, Weiss L, Staud C, McDougall JA, Chou CK. Variations of dose and electrode spacing for rat breast cancer electrochemical treatment. Bioelectromagnetics 2001; 22:205-11. [PMID: 11255217 DOI: 10.1002/bem.40] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Electrochemical treatment (EChT) with direct current delivered through implanted electrodes has been used for local control of solid tumors in humans. This study tested the hypothesis that rat breast cancer responses to EChT are dependent on electrode spacing and dose, and explored suitable parameters for treating breast cancers with EChT. Rat breast cancers were initiated by injecting 1 x 10(6) MTF-7 cells to the right mammary gland fat pad of Fisher 344 female rats. The rats were randomly divided into designated experimental groups when the tumors grew to approximately 2 x 2 x 2 cm. One hundred and thirty rats were used for a survival study and 129 for a pathology study. A 4-channel EChT machine was used to administer coulometric doses. The survival study indicated that local tumor control rate is less than 40% in the 40 coulomb (C) and 60 C groups and more than 70% in the 80 and 100 C groups. Sixty six rats died of primary tumors, including all 10 rats in the control group. Once a rat's primary tumor was controlled, no recurrence was found. The main reason for terminating the primary tumor-free rats (51) was lymph node metastasis. Thirteen tumor-free rats survived for more than 6 months. The pathology study showed a significant dose effect on EChT induced tumor necrosis. At 10, 20, 40, and 80 C, the fraction showing necrosis were 39.7, 52.3, 62, and 77.7%, respectively (P </= 0.001). Electrodes spacing was not an important factor within a given range. At 5, 10, and 15 mm spacing, the fraction showing the necrosis were 54.1, 60.4, and 59.2%, respectively (P = 0.552). The overlap rate of necroses was similar in the 5 and 10 mm groups (82.5 and 85%) and lower in the 15 mm group (65%). We conclude that the tumor responses to EChT, local control, survival rates, and necrosis percentages were significantly increased with increasing dose. The changes in electrode spacing (3, 5, and 10 mm) did not significantly affect the tumor responses to EChT within the same dose. For a diameter of 2.0-2.5 cm rat breast cancer, EChT should be applied with 5-10 mm spacing and a minimum dosage of 80 C.
Collapse
Affiliation(s)
- R L Ren
- Department of Radiation Research, City of Hope National Medical Center, Duarte, California, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Longmate J, York J, La Rosa C, Krishnan R, Zhang M, Senitzer D, Diamond DJ. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52:165-73. [PMID: 11220618 DOI: 10.1007/s002510000271] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Vaccination using cytotoxic T-lymphocyte (CTL) epitopes has become a widely used immunization strategy, especially because their structure makes them an attractive alternative to the delivery of whole proteins as immunogens. Nonetheless, their use is limited, in particular because of their specificity, being recognized only by cognate HLA alleles. The potential for immunizing a substantial portion of an ethnically diverse population using a modest number of peptides has been aided by the identification of HLA supertypes. However, the derivation of epitopes is often guided by methods that do not guarantee cross-reactivity, so we consider the feasibility of providing vaccine coverage to a multi-ethnic population under different assumptions. In particular, two large datasets are used to estimate the number of peptides needed to provide > or =90% group-specific coverage of a multiethnic population, when specificity is assumed to be either to a single serologic or molecular type. These assumptions are evaluated utilizing a clinically important epitope repertoire derived from two human cytomegalovirus proteins, and data on the in vitro memory response elicited by these peptides is presented. In summary, our combined theoretical and empiric studies suggest that 90% coverage of some ethnic groups is attainable with 11 uniquely defined HLA-restricted CTL epitopes. The derivation of four or more additional CTL epitopes is needed to attain 90% coverage of Blacks or Asians, the minimally covered groups. Ninety percent coverage of all major ethnic groups in a multi-ethnic population appears feasible without relying on cross-reactivity, but may require two to three times more CTL epitopes than estimated for serologic data, homogenous populations, or HLA alleles grouped as supertypes.
Collapse
Affiliation(s)
- J Longmate
- Department of Virology, Beckman Research Institute and the City of Hope National Medical Center, Duarte, CA 91010, USA
| | | | | | | | | | | | | |
Collapse
|
26
|
Han X, Lundberg P, Tanamachi B, Openshaw H, Longmate J, Cantin E. Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J Virol 2001; 75:3048-52. [PMID: 11222734 PMCID: PMC115935 DOI: 10.1128/jvi.75.6.3048-3052.2001] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Gender influences the incidence and severity of some bacterial and viral infections and autoimmune diseases in animal models and humans. To determine a gender-based difference, comparisons were made between male and female mice inoculated with herpes simplex virus type 1 (HSV-1) by the corneal route. Mortality was higher in the male mice of the three strains tested: 129/Sv//Ev wild type, gamma interferon (IFN-gamma) knockout (GKO), and IFN-gamma receptor knockout (RGKO). Similarly, in vivo HSV-1 reactivation occurred more commonly in male mice, but the male-female difference in reactivation was restricted to the two knockout strains and was not seen in the 129/Sv//Ev control. Comparison among male mice of the three strains showed a higher mortality of the RGKO mice and a higher reactivation rate of the GKO and RGKO mice than of the 129/Sv//Ev males. In contrast, female RGKO and GKO mice did not differ from female 129/Sv//Ev controls in either mortality or reactivation. HSV-1 periocular and eyelid disease was also more severe in male and dihydrotestosterone (DHT)-treated female mice than in control female mice. These results show a consistent gender difference in HSV-1 infection, with a worse outcome in male mice. In addition, the results comparing GKO and RGKO mice to controls show differences only in male mice, suggesting that some effects of IFN-gamma, a key immunoregulatory molecule, are gender specific.
Collapse
Affiliation(s)
- X Han
- Department of Virology, City of Hope National Medical Center, Duarte, California 91010, USA
| | | | | | | | | | | |
Collapse
|
27
|
Lara P, Law L, Reddy G, Edelman M, Doroshow J, Lau D, Lenz H, Israel V, Albain K, Jaslowski A, Longmate J, Frankel P, Gandara D. Salvage gemcitabine (GEM) in platinum-treated non-small cell lung cancer (NSCLC): A phase II California cancer consortium trial. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80187-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 2000; 61:764-79. [PMID: 10980387 DOI: 10.1016/s0198-8859(00)00139-7] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
CTL play a pivotal role in the immune response during viral infections. In this study, the HLA class II restricted T(H) requirement for optimal in vivo induction of HLA class I restricted CTL responses has been investigated. Towards this goal, transgenic mice expressing both HLA class I (A*0201 or A2.1) and class II (DRB1*0101 or DR1) molecules have been derived. Immunization of these mice with an HLA A*0201-restricted and CMV-specific CTL epitope (pp65(495-503)), and either of three different tetanus toxin-derived MHC class II-binding T(H) epitopes, resulted in a vigorous CTL response. CTL specific for the pp65(495-503) epitope were dramatically enhanced in mice expressing both the HLA-DR1 and HLA-A*0201 transgenes. Notably, preinjection of three TT peptides (TT(639-652), TT(830-843), and TT(947-967)) increased the capability of HLA A*0201/DR1 Tg mice to respond to subsequent immunization with the T(H) + CTL peptide mixture. These results indicate that the use of HLA A*0201/DR1 Tg mice constitute a versatile model system (in lieu of immunizing humans) for the study of both HLA class I and class II restricted T-cell responses. These studies provide a rational model for the design and assessment of new minimal-epitope vaccines based on their in vivo induction of a pathogen-specific CTL response.
Collapse
Affiliation(s)
- L BenMohamed
- Laboratory of Vaccine Research, the Department of Biostatistics, City of Hope National Medical Center, Duarte, California, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Morgan RJ, Braly P, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Najera L, Johnson D, Doroshow JH. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. Gynecol Oncol 2000; 77:433-8. [PMID: 10831355 DOI: 10.1006/gyno.2000.5793] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVES This trial was performed to determine the response rate and progression-free and overall survivals of patients with advanced recurrent ovarian cancer who were treated with intraperitoneal cisplatin and 5-fluorouracil. METHODS Twenty-four patients with ovarian cancer were entered on this trial and treated with intraperitoneal (ip) cisplatin (DDP) and ip 5-fluorouracil, every 3 weeks for eight cycles. Following iv hydration, the cisplatin and 5-fluorouracil were administered through an ip catheter in 2 liters of 0.9% normal saline with a 4-h dwell. RESULTS All patients were evaluable for progression-free and overall survival and toxicity analysis, and 22 patients for response. The median age was 59 (range, 35-71); initial disease status included 9 patients with residual disease following chemotherapy prior to entry on this study; 5 patients had progressed, and 10 patients had recurrent disease more than 6 months following initial chemotherapy. Of the 9 patients with residual disease, 1 complete response and 3 partial responses were observed; of 10 patients with recurrent disease, 1 complete and 1 partial response were observed for an overall response rate of 27%. No objective responses were seen in the 7 patients who were platinum-refractory on protocol entry. The median progression-free and overall survivals are 7.0 (range, 0.5-137) and 15.5 (range, 3-147) months, respectively. Toxicity included hypomagnesemia, vomiting, abdominal pain, and mild anemia. Only one patient required a dosage adjustment of cisplatin for a serum creatinine elevation >2.0 mg/dl. CONCLUSIONS We conclude that the combination of ip cisplatin and 5-FU is an effective regimen for patients with residual or relapsed epithelial ovarian cancer with survival durations, response rates, and toxicity profiles that compare favorably with those of other second-line ovarian cancer regimens. Patients who are primarily platinum-refractory are unlikely to benefit from these agents administered into the peritoneal cavity.
Collapse
Affiliation(s)
- R J Morgan
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, California 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Morgan RJ, Braly P, Cecchi G, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Parker P, Stein A, Cho J, Smith E, Coluzzi P, Najera L, Johnson D, Womack E, Doroshow JH. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up. Gynecol Oncol 1999; 75:419-26. [PMID: 10600300 DOI: 10.1006/gyno.1999.5613] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Forty-three patients with ovarian cancer were entered on this trial and treated with intravenous (iv) cyclophosphamide (C) and doxorubicin (A), and intraperitoneal (ip) cisplatin (DDP), every 21 days for eight cycles. Following iv hydration, the cisplatin was administered through an intraperitoneal catheter in 2 L of 0.9% normal saline with a 4-h dwell. All patients are evaluable for overall and progression-free survival with a median follow-up of 70 months (range: 3-162 months); 39 patients are evaluable for response. All complete responses were surgically confirmed. The median age was 59 (range 28-82 years); 3 patients were stage IC, 5 were IIC, 14 patients were stage III (optimally debulked), 14 patients were stage III (suboptimally debulked), and 7 patients were stage IV. Two patients had received prior alkylator therapy. Six of 8 patients with Stage IC or II remain without evidence of disease at a mean of 12 years following chemotherapy. Of 14 optimally debulked stage III patients, there were 7 complete responses, 3 partial responses, 1 patient with stable disease, and 3 inevaluable patients. Of 14 suboptimally debulked stage III patients there were 4 complete responses, 4 partial responses, 3 with stable disease, 2 progressions on treatment, and 1 inevaluable patient. Five-year progression-free and overall survivals for stage III optimally debulked patients are 21 and 64%, respectively. At 10 years, progression-free and overall survivals for this group are 21 and 29%, respectively. Toxicity included neutropenia (complicated by sepsis in 2 patients), infrequent thrombocytopenia, and mild anemia. Three patients developed transient serum creatinine elevations >2.0 mg/dl; however, decreased creatinine clearance was noted in 93/258 (36%) of evaluable courses which required a cisplatin dose reduction per protocol. Controllable hypomagnesemia, nausea, and emesis were also observed. We conclude that the combination of iv CA and ip DDP is an effective regimen with long-term progression-free and overall survivals that compare favorably with those of other published studies of intravenous or intraperitoneal chemotherapy. This report is unusual in terms of the prolonged follow-up for all patients enrolled. These long-term results lend further support to recently published trials documenting the efficacy of intraperitoneal chemotherapy for patients with this disease.
Collapse
Affiliation(s)
- R J Morgan
- Department of Gynecologic Oncology, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, California 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Larson GP, Zhang G, Ding S, Foldenauer K, Udar N, Gatti RA, Neuberg D, Lunetta KL, Ruckdeschel JC, Longmate J, Flanagan S, Krontiris TG. An allelic variant at the ATM locus is implicated in breast cancer susceptibility. Genet Test 1999; 1:165-70. [PMID: 10464642 DOI: 10.1089/gte.1997.1.165] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We have tested a simple procedure, disease association by locus stratification, for identifying breast cancer patients with pathogenetic allelic variants at several candidate loci. The strategy was based on the assumption of epistatic interactions of the candidates. We analyzed 66 independent cases from sib pairs affected with breast cancer that had previously been collected during an investigation of pathogenetic-allele-sharing at the HRAS1 mini-satellite locus. An exon 24 polymorphism of ATM, substituting arginine for proline was associated with breast cancer in these cases with an overall odds ratio of 4.5 (95% confidence interval, 1.2-20.5, nominal p = 0.02, 2-tail Fisher exact test). In the presence of a rare HRAS1 allele, the odds ratio increased to 6.9 (95% CI, 1.2-38.3, p = 0.03). Thus, our procedure identified at least one allelic variant of ATM associated with breast cancer, and indicated that the ATM locus may interact with HRAS1.
Collapse
Affiliation(s)
- G P Larson
- Division of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, Elfenbein GJ, Janiec J, Jansen J, Lazarus HM. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant 1999; 23:929-32. [PMID: 10338049 DOI: 10.1038/sj.bmt.1701742] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Intravenous immunoglobulin has been used after bone marrow transplants to prevent infections and acute graft-versus-host disease. However, the minimum dose required for protection is unknown. This may have significant economic implications. A multicenter randomized clinical trial compared the impact of two intravenous immunoglobulin doses on systemic infections and acute graft-versus-host disease in transplant recipients. Either 250 mg/kg or 500 mg/kg was given weekly from day -8 to day +111. Multivariate analysis was used to assess the effect of dose and other risk factors on event-free survival, systemic infection, and acute graft-versus-host disease. The two-dose cohorts had similar event-free survival and infection frequencies. The higher dose was associated with less acute graft-versus-host disease (P = 0.03).
Collapse
Affiliation(s)
- A Abdel-Mageed
- University of Florida, Pediatric Hematology/Oncology, Gainesville 32610-0296, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, Bhatia R, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow JH. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999; 93:2798-806. [PMID: 10216073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023] Open
Abstract
Lineage-specific growth factors mobilize peripheral blood progenitor cells (PBPC) and accelerate hematopoietic recovery after high-dose chemotherapy. Recombinant human thrombopoietin (rhTPO) may further increase the progenitor-cell content and regenerating potential of PBPC products. We evaluated the safety and activity of rhTPO as a PBPC mobilizer in combination with granulocyte colony-stimulating factor (G-CSF) in 29 breast cancer patients treated with high-dose chemotherapy followed by PBPC reinfusion. Initially, patients received escalating single doses of rhTPO intravenously (IV) at 0.6, 1.2, or 2.4 micrograms/kg, on day 1. Subsequent patients received rhTPO 0.6 or 0.3 micrograms/kg on days -3, -1, and 1, or 0.6 micrograms/kg on days -1 and 1. G-CSF, 5 micrograms/kg IV or subcutaneously (SC) twice daily, was started on day 3 and continued through aphereses. Twenty comparable, concurrently and identically treated patients (who were eligible and would have been treated on protocol but for the lack of study opening) mobilized with G-CSF alone served as comparisons. CD34(+) cell yields were substantially higher with the first apheresis following rhTPO and G-CSF versus G-CSF alone: 4.1 x 10(6)/kg (range, 1.3 to 17.6) versus 0.8 x 10(6)/ kg (range, 0.3 to 4.2), P =.0003. The targeted minimum yield of 3 x 10(6) CD34(+) cells/kg was procured following a single apheresis procedure in 61% of the rhTPO and G-CSF-mobilized group versus 10% of G-CSF-mobilized patients (P =.001). In rhTPO and G-CSF mobilized patients, granulocyte (day 8 v 9, P =.0001) and platelet recovery (day 9 v 10, P =.07) were accelerated, and fewer erythrocyte (3 v 4, P =.02) and platelet (4 v 5, P =.02) transfusions were needed compared with G-CSF-mobilized patients. Peripheral blood platelet counts, following rhTPO and G-CSF, were increased by greater than 100% and the platelet content of PBPC products by 60% to 110% on the first and second days of aphereses (P <.0001) with the greatest effect seen with repeated dosing of rhTPO at 0.6 microgram/kg. rhTPO is safe and well tolerated as a mobilizing agent before PBPC collection. Mobilization with rhTPO and G-CSF, in comparison to a comparable, nonrandomized G-CSF-mobilized group of patients, decreases the number of apheresis procedures required, may accelerate hematopoietic recovery, and may reduce the number of transfusions required following high-dose chemotherapy for breast cancer.
Collapse
Affiliation(s)
- G Somlo
- Departments of Medical Oncology and Therapeutics Research, Transfusion Medicine, and Biostatistics, City of Hope National Medical Center, Duarte, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Morgan RJ, Newman EM, Doroshow JH, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. Cancer Res 1998; 58:2793-800. [PMID: 9661893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
In this Phase I study, the maximally tolerated doses (MTDs) of i.p. iododeoxyuridine (IdUrd) alone and in combination with i.v. calcium leucovorin (LV) were determined. The pharmacokinetics and pharmacological advantage of IdUrd were evaluated, and flow cytometric analysis allowed examination of the extent of incorporation of IdUrd into tumor cells with and without the addition of i.v. LV. Thirty-nine patients with advanced neoplasms primarily confined to the peritoneal space were enrolled in a dose-escalation trial using 4-h dwells of IdUrd administered i.p. daily for 4 days with and without an i.v. infusion of LV 500 mg/m2/day for 4.5 days. Twenty-three patients received single-agent therapy, and 13 patients received i.p. IdUrd in combination with i.v. LV. The MTD of single-agent IdUrd administered on this schedule was 4125 mg/m2/day for 4 days; and that of the IdUrd in combination was 3438 mg/m2/day. Dose-limiting toxicities were myelosuppression and stomatitis. During the period of the dwell, the peritoneal AUC (area under the curve) of IdUrd exceeded the plasma AUC of IdUrd by one or two orders of magnitude in all patients at all doses tested; there was a possible effect of LV on peritoneal AUC. The geometric mean pharmacological advantage (AUCperitoneal/ AUCplasma) was 181 at 625 mg/m2/day and 90 at 4538 mg/m2/day. Flow cytometric analysis suggests saturation of IdUrd measured in DNA at the 2500-3125 mg/m2 dose level, without an increase after the addition of LV. Twelve patients received 4-12 courses of therapy. One patient with recurrent ovarian cancer who received 16 courses of therapy experienced complete resolution of her ascites, near normalization of CA-125 levels, and improved quality of life; two patients with high-risk tumors receiving "adjuvant" therapy are disease-free at 3 and 6 years after treatment; other patients experienced transient clearing of ascites. The recommended Phase II dose of i.p. IdUrd using a 4-h dwell daily for 4 days is 3750 mg/m2/day alone or 3125 mg/m2/day in combination with continuous i.v. LV at 500 mg/m2/day for 4.5 days. Although flow cytometric data suggest that DNA incorporation of IdUrd is not affected by the addition of LV, the cytotoxicity of the combination regimen may be increased due to LV-enhanced, IdUrd-related inhibition of thymidylate synthase. For this reason, we recommend that efficacy studies of the combination continue in parallel with studies of IdUrd alone.
Collapse
Affiliation(s)
- R J Morgan
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Marker-assisted selection protocol (MASP)-based strategies produce congenic strains with the target gene contained on clearly defined donor-derived genomic intervals in less than half the member of generations required by the classic protocol. Thus, the quality and speed of congenic strain construction are enhanced by this methodology. Here, Edward Wakeland and colleagues compare various MASP-based strategies and discuss their advantages with reference to immunological traits.
Collapse
Affiliation(s)
- E Wakeland
- Center for Mammalian Genetics, College of Medicine, University of Florida, Gainesville 32610-0275, USA.
| | | | | | | | | |
Collapse
|
36
|
Abstract
Though dental composite materials leach filler elements when stored in distilled water, it is not known whether similar leaching occurs in saliva. The hypothesis to be tested was that due to ion exchange occurring at the filler surfaces, more filler elements leach from composites stored in a salt solution simulating saliva than from composites stored in distilled water. Another aim was to determine how matrix selection, filler composition, and filler silanization affect filler leachability of composites after storage in the simulated saliva and water media. We made 128 batches of experimental composites. Half of these used a bis-GMA/TEGDMA matrix and the other a UEDMA/TEGDMA matrix. Either silica or barium glass filler particles were incorporated into these matrices. Filler silanization was followed by a filler drying at 60 degrees C for 24 h. Half of the silanized particles received an additional heat treatment for 1 h at 110 degrees C in vacuum. One specimen per batch was stored in distilled water and the other in artificial saliva at 37 degrees C. After each 30-day interval for one year, the specimens were transferred to either freshly distilled water or newly mixed artificial saliva. The "old" solutions were analyzed by ICP for determination of the Si, Ba, and Al concentrations. Analysis of variance revealed that storage solution, filler composition, and total time in the storage solution had strong effects on the leachability (p < 0.0001 in all cases). The average monthly leakage of Si for quartz-filled composites was 0.22 +/- 0.20 microgram/mL (distilled water) and 2.80 +/- 1.20 microgram/mL (artificial saliva). For barium-glass-filled composites, the corresponding Si leaching values were 0.73 +/- 0.48 microgram/mL and 5.00 +/- 2.20 microgram/mL. The monthly means of the barium leaching values were 2.00 +/- 1.00 microgram/mL (distilled water) and 3.10 +/- 1.80 microgram/mL (artificial saliva). The large difference between leaching in artificial saliva and in distilled water, as well as the interaction between storage medium and filler, cast doubt on the clinical relevance of in vitro studies using distilled water.
Collapse
Affiliation(s)
- K J Söderholm
- Department of Dental Biomaterials, University of Florida, Gainesville 32610-0446, USA
| | | | | |
Collapse
|
37
|
Abstract
During the past few years, the interest in using ceramic inlays and veneers has increased. New materials and methods have been introduced to bond these restorations to resinous materials. Since our knowledge of how to optimize such bonding is limited, the objective of this study was to test the hypothesis that various surface treatment variables and combinations of these variables affect the strength of the ceramic/composite interphase of ceramic inlays differently. The influences of material composition, surface-roughening method, silane treatment, silane heat treatment, and storage condition on bond strength were investigated. Three ceramics (Dicor, Mirage, Vitabloc), three surface-roughening methods (etching, sandblasting, grinding), three silane treatments (gamma-methacryloxypropyltrimethoxysilane [MPS], MPS+paratoluidine, vinyltrichlorosilane), two heat treatments (20 degrees C for 60 s, 100 degrees C for 60 s), and two storage conditions (24-hour dry, one yr in water at 37 degrees C) were studied. For each of the 108 combinations, five specimens were tested. Ceramic cylinders were treated according to group assignment and bonded to blocks of the same ceramic material with a dual-cured resin. The shear bond strength was determined, and the experimental factors were evaluated by analysis of variance. The results showed that surface-roughening method had the strongest effect on bond strength, while ceramic selection had the least significant effect. Of the surface-roughening methods, etching was associated with higher bond strength values than either sandblasting or grinding.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J F Roulet
- Department of Operative Dentistry and Endodontics North, Freie Universität Berlin, Germany
| | | | | |
Collapse
|
38
|
Abstract
Military veterans eligible for dental care in U.S. Department of Veterans Affairs (VA) facilities cooperated for a mailed survey about their dental care utilization. Subjects were selected because of their eligibility for continuing dental care in VA facilities at no monetary cost. However, only 48% reported the VA as their only or primary source of dental care; this allowed us the opportunity to compare dental care frequency by those who received dental care at no monetary cost with those who did not, as well as measure delivery system effects on dental care use. Consequently, we tested respondent-level and delivery system-level hypotheses regarding determinants of veterans' dental care use. Predisposing characteristics (dentate status, usual reason for dental visits, and the importance placed on dental care and oral health) were the strongest determinants of interval since last dental visit. Enabling determinants (current source of dental care, and having a regular source of care) were also significant, but measures of need for dental care (perceived oral health and perceived need for treatment) were not. More recent dental care use by veterans who used the VA delivery system as their source of dental care, even with dental care payment source and other determinants accounted for, suggests that the VA delivery system may have promoted more regular use compared to other systems.
Collapse
Affiliation(s)
- G H Gilbert
- Department of Oral and Maxillofacial Surgery, College of Dentistry, University of Florida, Gainesville 32610
| | | | | |
Collapse
|
39
|
Abstract
The performance of four automated biopsy devices (Bard Biopty, Bard Monopty, Microvasive ASAP 18, Medical Device Technologies Ultra-Cut) was compared when they were used to obtain 96 liver and 96 kidney samples from eight dogs under ultrasound guidance. There was no significant difference in the lengths of the samples obtained with the four devices. The Monopty device yielded a significantly greater mean weight of both kidney (30.8%) and liver (31.6%) samples compared with the other devices. There were no significant differences between the four devices relative to cellular and histologic preservation, crush artifact, and number of renal glomeruli or liver lobules and portal triads. Renal subcapsular hematomas were identified in most instances, and there was no difference between the devices in the amount of renal trauma resulting from their use. There was only one instance of severe injury to the liver. The choice of instrument should remain one of personal preference, since all four devices were satisfactory and none produced significantly greater renal or hepatic injury.
Collapse
Affiliation(s)
- C R Mladinich
- Department of Radiology, College of Medicine, University of Florida, Gainesville 32610-0374
| | | | | | | | | |
Collapse
|
40
|
Abstract
Veterans who were eligible for dental care in Department of Veterans Affairs (VA) facilities at no monetary cost responded to a mailed questionnaire. Seventy-one percent were aware that they were actually eligible for VA dental care. However, only 48 percent reported the VA as their only or primary source of dental care. Eligibility status, perceived quality of VA dental care, use of VA medical care, perception that one's income meets expenses, and perceived need for dental care were significant correlates of using the VA as one's current source of dental care. Level of formal education, perception that one's income meets expenses, transportation pattern, geographic distance from a VA facility, and eligibility status were significant correlates of using the VA as one's current medical care source. Research on VA utilization offers the opportunity to study issues of access to, and use of, a large public health care system whose patients largely receive care at no monetary cost. Veterans' use of VA dental and medical care is apparently influenced by a wide variety of factors, ranging from barriers to access to non-VA systems, to characteristics of the VA delivery system itself, to need for treatment.
Collapse
Affiliation(s)
- G H Gilbert
- Department of Oral and Maxillofacial Surgery, Claude D. Pepper Center for Research on Oral Health in Aging, College of Dentistry, University of Florida Health Science Center, Gainesville 32610-0416
| | | | | |
Collapse
|
41
|
Gilbert GH, Longmate J, Branch LG. Factors influencing the effectiveness of mailed health surveys. Public Health Rep 1992; 107:576-84. [PMID: 1410240 PMCID: PMC1403701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The authors investigated sources of bias in health surveys by examining responses to their 1989 questionnaire mailed to 1,255 Massachusetts men who were eligible for dental care provided by the Department of Veterans Affairs. After a maximum of three mailings and one telephone call to nonrespondents, a total of 1,049 veterans had responded out of 1,228 finally determined to be eligible, a response rate of 85 percent. The investigators found that small differences in univariate estimates would have occurred had the field phase been terminated after the first mailing, which had a response rate of 61 percent. To evaluate multivariate distributions, they duplicated their previously published logistic regression model for sources of dental care, using only those who responded to the first and second mailings. Although model fits would have been substantively the same had the field phase been terminated after the first or the second mailings, analysis of parameter estimates and their statistical significances suggested bias that would have led to different substantive conclusions, in some instances. Another potential source of bias in surveys was found to be item omission. Fifty-eight percent of respondents answered all 46 survey questions, and 90 percent answered at least 91 percent of the questions. Fewer questions were answered by those whose responses were received last, but trends regarding missing data by age or education were not statistically significant. Although the survey using this methodology met all objectives, subject nonresponses, the ineligibility of potential respondents, item nonresponses, and skewed distributions of outcome variables combined to reduce the statistical power to detect differences among groups or to alter the analysis of the differences. These factors need to be planned for by investigators undertaking similar surveys.
Collapse
Affiliation(s)
- G H Gilbert
- University of Florida, Department of Oral and Maxillofacial Surgery, Gainesville 32610-0416
| | | | | |
Collapse
|
42
|
Floros J, Phelps DS, deMello DE, Longmate J, Harding H, Benson B, White T. The utility of postmortem lung for RNA studies; variability and correlation of the expression of surfactant proteins in human lung. Exp Lung Res 1991; 17:91-104. [PMID: 1707362 DOI: 10.3109/01902149109063284] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Postmortem human lung tissue was evaluated for its utility in studies of the mRNAs for the surfactant proteins. Data obtained from different analytical procedures indicated that surfactant protein mRNAs are quite stable in these tissues with a half-life of 10 to 12 h. These analyses revealed no major regional differences in the mRNA levels for the surfactant protein A (SP-A) and surfactant protein B (SP-B) although small differences were present in the levels for the surfactant protein C (SP-C). Analysis of adult surgical lung specimens indicated that there is greater individual variation in the mRNA levels for SP-A and SP-B compared to SP-C among individuals. Furthermore, in a given individual the level of SP-A mRNA correlated well with that of SP-B, whereas the level of SP-C mRNA did not correlate with either that of SP-A or SP-B.
Collapse
Affiliation(s)
- J Floros
- Deprtment of Pediatrics, Harvard Medical School, Boston, MA 02115
| | | | | | | | | | | | | |
Collapse
|